covid-19 vaccination in new zealand covid-19 vaccination in new zealand covid-19 vaccination in new zealand began on 20 february 2021, and will continue throughout the pandemic with the goal of vaccinating all willing new zealanders aged 5 or older. those aged 5 to 11 require a parent, caregiver or legal guardian accompany them to their appointment and provide consent for them to be vaccinated. as of 1 september, anyone in new zealand, regardless of their immigration status, is eligible to be vaccinated. first generation vaccine card second generation vaccine card part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal a photo of the new zealand governments vaccine campaign billboard vaccination rates in new zealand as of 11:59pm 26 february 2022 for 12+. fully vaccinated with boosters (55.45%) immunocompromised people who have received third shot (0.79%) fully vaccinated only (37.81%) only one dose (1.43%) booked (0.09%) unvaccinated/not booked (4.43%) vaccination rates in new zealand as of 11:59pm 26 february 2022 for 5-11. fully vaccinated (0.64%) only one dose (50.22%) booked (0.40%) unvaccinated/not booked (49.39%) covid-19 vaccination programdose 1 vaccination uptake per 1,000 residents, by sa2 area as of 17 novemberdate20 february 2021 (2021-02-20) – presentlocationnew zealand (aotearoa)causecovid-19 pandemic in new zealandtargetimmunisation of new zealand against covid-19organised byministry of health, district health boards (until 30 june 2022), department of the prime minister and cabinet, health new zealand (from 1 july 2022) and māori health authority / te mana hauora māori (from 1 july 2022)participants 4,027,888 people aged 12+ have received one dose of covid-19 vaccine 3,979,957 people aged 12+ have been fully vaccinated with two doses of covid-19 vaccine 32,533 people whom are immunocompromised aged 12+ have received a third primary dose 2,665,867 people aged 18+ have received a booster dose outcome 86% of the eligible new zealand population aged 5+ have received one dose 84.9% of the eligible new zealand population aged 5+ are fully vaccinated websitecovid19.govt.nz/health-and-wellbeing/covid-19-vaccines/ vaccine tracker the ministry of health releases vaccine numbers almost daily. there are no planned vaccination statistics from 30 august onwards. the increased vaccination demand caused by the august 2021 outbreak means the plans collected earlier do not provide a good comparator to actual vaccination numbers. the following graphs are as of 11:59pm on 7 december 2021 nzdt. daily vaccinations chart of new zealand cumulative vaccinations in new zealand percentage of eligible population fully vaccinated by ethnicity planned vs received vs actual vaccination numbers vaccine approval the new zealand government's primary vaccine, and booster vaccines, is the pfizer–biontech covid-19 vaccine. the astrazeneca covid-19 vaccine is available for anyone aged 18 years and older from 29 november 2021 who either wants a different option or if they cannot get the pfizer vaccine. currently, three vaccines have been approved by government regulator medsafe; pfizer–biontech, janssen, and oxford–astrazeneca. they are approved under section 23 of the medicines act, with conditions. medsafe has received an application for the novavax covid-19 vaccine, with some data under evaluation, and further data to be provided by the applicants. the vaccine is currently not approved. vaccine status vaccine name approval progress quantity doses required vaccine approved began administering pfizer–biontech approved for use 10 million 2 03 feb 2021 20 feb 2021 janssen approved for use 5 million 1 07 jul 2021 not yet oxford–astrazeneca approved for use 7.6 million 2 22 jul 2021 29 november 2021 novavax approved for use 10.72 million 2 04 feb 2022 not yet vaccines in trial stage vaccine type (technology) phase i phase ii phase iii no. of participants in clinical trial recov subunit in progress pending pending 160 cov2-ogen1 subunit not yet pending pending 45 valneva inactivated pending pending pending 300 vaccine roll out plan covid-19 vaccine rollout plan order priority group number eligible (estimated) doses administered as of 11:59 pm 26 october 2021 status group 1 1a border/miq workforce 66,451 dose 1: 66,767dose 2: 65,205 in progress 1b families and household contacts group 2 2a frontline healthcare workers (non-border) who could be exposed to covid-19 while providing care 661,183 dose 1: 661,231dose 2: 621,689 in progress 2b frontline healthcare workers who may expose vulnerable people to covid-19 2b at-risk people living in settings with a high risk of transmission or exposure to covid-19 2b new zealand defence force 2b frontline staff who interact with customers and transport and logistic services directly supporting the vaccination programme group 3 3a people aged 75+ 1,700,000≈ dose 1: 793,481dose 2: 746,741 in progress 3b people aged 65+ 3c people with underlying health conditions or disabilities, or 3c are disabled, orare in a position of caring for a person with a disability, orare pregnant (any trimester), orare an adult in a custodial setting. group 4 4 people aged 60 and over 2,136,481 dose 1: 2,136,491dose 2: 1,585,195 in progress people aged 55 and over people aged 50 and over people aged 40 and over people aged 30 and over people aged 12 and over other groups – new zealand olympic team 220 dose 1: 220dose 2: 220 completed – new zealand paralympic team 29 dose 1: 29dose 2: 29 completed – special forces in operation kōkako 80 dose 1: 80dose 2: 80 completed the following reasons for overseas travel are eligible to be considered for an early vaccine: access critical medical care that is not available in new zealand for yourself or your dependent to visit an immediate family member who is dying to provide critical care and protection for a dependent e.g., your child. to protect the safety and security of new zealand's right to govern itself for government-approved humanitarian efforts as part of new zealand's commitments to foreign aid, international disaster responses, or supporting pacific and realm countries' recovery from the covid-19 pandemic to participate in major international events where travel is necessary to represent new zealand for nationally significant trade negotiations. history unofficial initiatives in late august 2020, stuff reported that several businessmen and former politicians (including former national mp ross meurant and former national party and act party leader don brash) had sought to import russia's insufficiently tested gam-covid-vac (also known as sputnik v) vaccine into new zealand. they had established a company called covax-nzr limited and filed paperwork through the russian embassy to establish supply and distribution arrangements to import the vaccine. ross meurant is the only director and shareholder of the company. university of auckland vaccinologist helen petousis-harris warned that using untested vaccines could hurt global efforts to develop safe and effective vaccines against covid-19. on 17 august 2021, the french biotech company valneva began trialing the their covid-19 vaccine in coordination with pharma sols. the company is looking for 300 adults in new zealand who are over the age of 56 years, have not contracted covid-19 or received a covid-19 vaccine. the new zealand clinical trial will take place at eight pacific research network sites across the country. according to the new zealand trial's lead coordinating investigator and southern clinical trials christchurch director dr. simon carson, new zealand was chosen due to the country's lower case numbers and slower vaccine rate. official procurement efforts on 12 october 2020, the new zealand government signed an agreement with pfizer and biontech to buy 1.5 million doses of the pfizer-biontech covid-19 vaccine, which is enough for 750,000 people. the covid-19 vaccine strategy task force also entered into negotiations with other pharmaceutical companies to provide vaccines. in addition, the government established a fund of $66.3 million to support a covid-19 immunisation programme as soon as the vaccine is ready. on 17 december, prime minister jacinda ardern announced that the new zealand government had purchased two more vaccines for new zealand, the cook islands, niue, tokelau and its pacific partners samoa, tonga, and tuvalu from the pharmaceutical companies astrazeneca and novavax. the government had purchased 7.6 million doses (enough for 3.8 million people) from astrazeneca and 10.72 million doses (enough for 5.36 million people) from novavax. both vaccines require two doses to be administered. both vaccines will be free for new zealanders. the government had already purchased 750,000 courses from pfizer/biontech and 5 million from janssen pharmaceutica. on 3 february 2021, ardern provisionally approved the pfizer-biontech covid-19 vaccine for use in new zealand. the initial batches of the vaccine are scheduled to arrive in late march 2021, with frontline workers and the vulnerable given priority. by 10 february, the government had formally authorised the pfizer-biontech covid-19 vaccine for use in new zealand. the vaccine will be limited to people aged 16 years and over. by 8 march, the new zealand government had secured an additional 8.5 million doses of the pfizer-biontech covid-19 vaccine on 4 november, the us pharmaceutical company novavax applied for provisional approval from medsafe to use its covid-19 vaccine in new zealand. on 10 november, the government announced that the oxford–astrazeneca covid-19 vaccine would be made available from late november 2021 for a small number of people aged 18 or over who are medically unable to get the pfizer vaccine. booster shots in early august 2021, director-general of health ashley bloomfield confirmed that the ministry of health was negotiating with pharmaceutical company pfizer about acquiring booster vaccines to counter possible waning immunity. following the august 2021 delta outbreak, the opposition national party covid-19 spokesperson chris bishop called on the government to purchase pfizer booster shots urgently. this call clashed with the world health organizations' advice that there was insufficient evidence they were needed and that wealthy countries buying up vaccine stocks would make it harder for poorer countries to acquire their first doses. on 25 august 2021, a national party social media post claiming that excess vaccine stocks are not boosters was criticised for inaccuracy by the scientists helen petousis-harris and alison campbell. vaccine diplomacy on 16 april 2021, jacinda ardern announced that new zealand would donate 1.6 million covid-19 vaccine doses through an international vaccine sharing programme. this quantity will be enough to vaccinate 800,000 people, many of whom will be health workers and vulnerable people in the pacific islands. during the announcement, ardern also advocated a "team of 7.8 billion," based on the